Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radiolabelled somatostatin peptides

Drug Profile

Radiolabelled somatostatin peptides

Alternative Names: MK 678-derived somatostatin peptides; Seglitide analogue; Somatoscan; Somatostatin peptides; Somatostatin Therapy

Latest Information Update: 13 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DRAXIS Specialty Pharmaceuticals
  • Class Antineoplastics; Cyclic peptides; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 13 Sep 2007 No development reported - Preclinical for Cancer diagnosis in Canada (unspecified route)
  • 13 Sep 2007 No development reported - Preclinical for Cancer in Canada (unspecified route)
  • 10 Feb 2005 Preclinical trials in Cancer diagnosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top